Kura Oncology to Participate in Credit Suisse Healthcare Conference
November 02, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
October 18, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
September 07, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
July 06, 2021 07:30 ET
|
Kura Oncology, Inc.
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors – – HNSCC accounts for more than 500,000 new cancer cases each...
Kura Oncology Appoints Carol Schafer to Board of Directors
June 04, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
May 13, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2021 Financial Results
May 06, 2021 16:04 ET
|
Kura Oncology, Inc.
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion...
Kura Oncology to Report First Quarter 2021 Financial Results
April 29, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
May 29, 2020 08:00 ET
|
Kura Oncology, Inc.
– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8...
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
May 13, 2020 17:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...